GlassScriptPhysician profile
Mary E Rudloff
NPI 1407841356
$5,647.68
in general payments reported to CMS, 2019-2025
30 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $808 · 2023: $1,198 · 2024: $1,521 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,045.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,846.16 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $1,405.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $591.05 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.58 | 2022-2025 | Jardiance |
| Esperion Therapeutics, INC. | $179.41 | 2021-2024 | Nexletol, Nexlizet |
| Pfizer INC. | $176.39 | 2021-2025 | |
| Glaxosmithkline, LLC. | $141.79 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Paratek Pharmaceuticals, INC. | $122.32 | 2024-2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $109.40 | 2022-2025 | |
| Abbvie INC. | $100.15 | 2022 | |
| Boston Scientific Corporation | $89.63 | 2025 | Watchman Flx |
| Sumitomo Pharma America, INC. | $89.40 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $82.57 | 2021-2024 | Xarelto |
| Axsome Therapeutics, INC. | $72.83 | 2025 | Auvelity |
| Exact Sciences Corporation | $68.49 | 2023-2024 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $55.95 | 2023 | Belsomra, Steglatro |
| Viatris Specialty LLC | $48.34 | 2025 | Yupelri |
| Lundbeck LLC | $45.46 | 2024-2025 | Rexulti |
| 3b Medical, INC. | $30.13 | 2024 | Luna |
| Sanofi-Aventis U.S. LLC | $26.19 | 2021-2022 | |
| Abbott Laboratories | $23.22 | 2023 | Freestyle Libre 3 |
| Insulet Corporation | $21.86 | 2024 | Omnipod |
| Advanced Oxygen Therapy INC. | $19.58 | 2023 | Topical Oxygen Chamber For Extremities |
| Phathom Pharmaceuticals, INC. | $18.73 | 2024 | Voquezna |
| Amgen INC. | $17.67 | 2021 | |
| Astellas Pharma US INC | $16.92 | 2023 | Veozah |
| Dexcom, INC. | $16.76 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $16.31 | 2023 | Quviviq |
| Medtronic, INC. | $13.31 | 2021 | |
| Mylan Specialty L.P. | $13.28 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Rudloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.